Frontlight ResearchEarly access
Enrolling by invitationNo phase
An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the siteAlso in 1 other country, 1 site
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 70 people, planned
- Started
- 26 Sept 2019
- Expected to end
- Aug 2040
- Type of study
- Observational
- Treatments tested
- autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
- Record updated
- 18 December 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- A patient is eligible for enrollment in the study if all of the following criteria are met:
- the patient has been treated with an autologous ex vivo gene therapy product based on the EFS-ADA LV, as part of the OTL-101 clinical development program
- the patient displays persistent detectable gene marking, as determined by the Investigator
- the patient or, if applicable, the patient's parent(s)/legal guardian(s), are able and willing to provide informed consent
Who cannot take part
- There are no exclusion criteria for participation in this observational LTFU study
Where in United States
Also in 1 other country, 1 site
- Mattel Children's Hospital UCLA/Ronald Reagan UCLA Medical CenterLos Angeles, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This observational long-term follow-up study is designed to collect safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA LV encoding for human adenosine deaminase (ADA) gene (EFS-ADA LV), as part of the OTL-101 clinical development program. No investigational medicinal product will be administered to these patients as part of the OTL-101-6 study.
Treatments tested
- autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Observational Long-term Follow-up Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)
- Publications
- Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.The New England journal of medicine, 2025
- Record updated
- 18 December 2025